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Diabetic peripheral neuropathy (DPN) and diabetic kidney disease (DKD) are common diabetic
complications with limited treatment options. Experimental studies show that targeting inflam-
mation using chemokine receptor (CCR) antagonists ameliorates DKD, presumably by reducing
macrophage accumulation or activation. As inflammation is implicated in DPN development,
we assessed whether CCR2 and CCR5 antagonism could also benefit DPN. Five-week-old ob/
ob mice were fed a diet containing MK-0812, a dual CCR2-CCR5 receptor antagonist, for
8 weeks; DPN, DKD and metabolic phenotyping were then performed to determine the effect
of CCR inhibition. Although MK-0812 reduced macrophage accumulation in adipose tissue, the
treatment had largely no effect on metabolic parameters, nerve function or kidney disease in
ob/ob mice. These results conflict with published data that demonstrate a benefit of CCR
antagonists for DKD and hyperglycaemia. We conclude that CCR signaling blockade is ineffec-
tive in ob/ob mice and suspect that this is explained by the severe hyperglycaemia found in this
model. It remains to be determined whether MK-0812 treatment, alone or in combination with
improved glycaemic control, is useful in preventing diabetic complications in alternate animal
models.
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1 | INTRODUCTION
Systemic inflammation, primarily driven by adipose tissue dysfunc-
tion, is recognized as an underlying contributor to the development
of type 2 diabetes (T2D).1 Inflammation is also implicated in diabetic
kidney disease (DKD) and diabetic peripheral neuropathy (DPN),
2 common microvascular complications of T2D.2,3 As T2D patients
manifest with hyperglycaemia, current prevention strategies focus on
Received: 10 January 2017 Revised: 13 March 2017 Accepted: 19 March 2017
DOI: 10.1111/dom.12950
1468 © 2017 John Wiley & Sons Ltd wileyonlinelibrary.com/journal/dom Diabetes Obes Metab. 2017;19:1468–1472.
glycaemic control; however, this approach does not guarantee pro-
tection from DKD or DPN.4,5 Thus, targeting inflammation may pro-
vide an adjuvant therapy for the prevention of diabetic
complications.
A hallmark of DKD is leukocyte accumulation, including macro-
phages, within the kidney glomerulus where they secrete pro-
inflammatory proteins such as tumor necrosis factor alpha (TNFα),
promoting inflammation and subsequent kidney injury.3 Indeed, mac-
rophage accumulation strongly correlates with renal dysfunction in
patients with DKD.6 Although not as well characterized, studies sup-
port a similar inflammatory mechanism in DPN.7,8
During initial tissue injury, resident leukocytes become activated
and secrete chemokines that bind to chemokine receptors (CCRs)
found on circulating leukocytes. This chemokine-CCR signaling facili-
tates trafficking of circulating leukocytes to the site of injury where
they propagate inflammation. Unlike inflammation triggered by exter-
nal pathogens, metabolic inflammation is difficult to resolve, leading
to low-grade, chronic activation of the immune response.1 Sustained
inflammation promotes leukocyte accumulation in the damaged tis-
sue, the continued production of pro-inflammatory mediators, and
amplification of the inflammatory response via a positive feedback
loop. Chemokine C-C ligand-2 (CCL2) is responsible for recruiting
CCR2-expressing leukocytes, including macrophages, to sites of
inflammation. Antagonizing CCL2 signaling attenuates features of
T2D in mouse models by preventing leukocyte infiltration into adi-
pose tissue.9 Importantly, these benefits appear to extend to diabetic
complications, as CCR2 antagonism reduces renal tissue inflammation
and ameliorates DKD in mouse models of T2D.10 Likewise, in
patients with DKD, treatment with a CCR2 antagonist or an inhibitor
of CCL2/MCP1 can reduce proteinuria.11 Though less well studied,
CCL5-CCR5-mediated signaling has also been implicated in T2D
patients and rodent models of DKD12; however, unlike DKD, CCR2
and CCR5 activation in DPN has not yet been examined.
We recently completed microarray gene expression analyses and
reported that biological pathways related to inflammation, including
chemotaxis, immune response and response to wounding, are dysregu-
lated in the sciatic nerve of ob/ob and db/db mice.13 Moreover, the
expression levels of chemokines Ccl2, Ccl4 and Ccl8, ligands for CCR2
and CCR5, were increased in sciatic nerve tissue of ob/ob mice. These
data suggest that, similar to DKD, chemokine-CCR signaling is involved
in DPN. Therefore, we tested whether blocking CCR2- and CCR5-
mediated chemokine signaling would prevent DPN as well as DKD in
ob/ob mice, a mouse model of both microvascular complications.13,14
2 | RESEARCH DESIGN AND METHODS
2.1 | Animals and diets
Male ob/+ and ob/ob mice (BTBR.Cg-Lepob/WiscJ) were fed a stand-
ard diet (11.5% kcal fat) or a diet containing MK-0812 (10 mg/kg/
mouse) ad libitum from 5 to 13 weeks of age. Fasting blood glucose
(FBG), percent glycated haemoglobin (%GHb) and plasma insulin were
measured at study conclusion. Additional details into experimental
procedures are described in Appendix S1, Supporting Information.
Details on the pharmacokinetic profile (Table S2) and primer
sequences for gene expression analysis (Table S3) are provided in
Supporting Information.
2.2 | DPN and DKD phenotyping
DPN and DKD phenotyping was performed on the same animals in
accordance with Diabetic Complications Consortium guidelines
(http://www.diacomp.org) and is described in Appendix S1, Support-
ing Information. Briefly, DPN phenotyping consisted of assessing
hindpaw withdrawal from a thermal stimulus, sensory and motor
nerve conduction velocities (NCV), and intraepidermal nerve fiber
(IENF) density; DKD phenotyping consisted of measuring urinary
albumin excretion (UAE), the albumin creatinine ratio (ACR), and the
mesangial index quantified by calculating the percentage of the total
glomerular tuft area that was PAS-positive.
2.3 | Statistical analysis
Statistical analysis consisted of one-way ANOVA with Tukey’s post-
test for multiple comparisons or Kruskal-Wallis test with Dunn’s
FIGURE 1 Effects of MK-0812 on metabolic parameters. Terminal
FBG (A), GHb% (B), body weight (C), collective weight of adipose
tissue depots (D), eWAT weight (E) and insulin (F). ***P < .0001 ob/
ob mice vs ob/+ mice. δδP < .001 MK-0812-treated ob/+ and ob/ob
mice vs respective non-treated controls
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post-test for multiple comparisons, as appropriate, using GraphPad
Prism Software, Version 6 (GraphPad Software, La Jolla, California).
Error bars represent SEM (n = 6 mice/group). A P value of <.05 was
considered statistically significant.
3 | RESULTS
3.1 | MK-0812 treatment does not affect FBG, %
GHb, insulin or body weight
At 13 weeks, ob/ob mice had increased FBG, %GHb and insulin when
compared to non-diabetic controls (Figure 1A,B,F). Body weight was
similar in ob/+ and ob/ob mice (Figure 1C); however, the increase in
total adipose tissue mass in ob/ob mice (Figure 1D) suggests that ob/
+ mice have greater lean muscle mass. MK-0812 had no effect on
FBG, weight, total adipose mass or insulin levels in ob/+ or ob/ob
mice (Figure 1A,C,D,F) and only a modest effect on %GHb
(Figure 1B). Moreover, MK-0812 treatment increased eWAT mass in
ob/ob mice (Figure 1E).
3.2 | MK-0812 treatment does not prevent
development of diabetic microvascular complications
DPN and DKD measures were examined in ob/ob mice to determine
the effects of MK-0812 on diabetic complications. ob/ob mice devel-
oped DPN, with increased hindpaw withdrawal latency (Figure 2A),
reduced IENF (Figure 2B) and reduced sensory (Figure 2C) and motor
(Figure 2D) NCV compared to ob/+ mice. ob/ob mice also exhibited
features of DKD, with increased ACR (Figure 2E), polyuria
(Figure 2F), mesangial matrix expansion (Figure 2G) and glomerular
thickening (Figure 2H). MK-0812-treated ob/ob mice showed no
improvement in diabetic nerve (Figure 2A-D) or kidney changes
(Figure 2E-H) relative to untreated controls, indicating that MK-0812
treatment did not prevent DPN or DKD.
3.3 | Effects of MK-0812 treatment on systemic,
neuronal, renal and adipose inflammation
To determine the effects of MK-0812 treatment on systemic and
local inflammation, a cytokine/chemokine multiplex array was per-
formed on plasma and nerve (SCN/DRG) and kidney (glomerulus)
tissue lysates. Interestingly, little to no difference in inflammatory
protein levels was observed between ob/ob mice and ob/+ mice in
plasma or tissue (Table S1, Supporting Information). The multiplex
data were validated by more sensitive ELISAs for plasma TNF-α, IL-
6 and CCL2 (Figure S1, Supporting Information). As adipose tissue
inflammation drives insulin resistance and is implicated in T2D
development,1 changes in markers of macrophage inflammation
were also assessed in eWAT. ob/ob mice had increased mRNA
expression of inflammation-related mediators, including Cd68,
F4/80, Pai-1 and Tnfα (Figure 2A-D), while MK-0812 treatment
decreased expression of Cd68, F4/80 and Tnfα (Figure S2, Support-
ing Information). These data suggest that MK-0812 effectively sup-
pressed macrophage infiltration in ob/ob adipose tissue.
4 | DISCUSSION
Recruitment of leukocytes to kidney tissue during T2D is an early
event in the pathogenesis of DKD,10 and evidence suggests a similar
mechanism in DPN.2 Previously, we reported that ob/ob mice
develop an early and robust DPN, with transcriptomic bioinformatics
analysis implicating “chemotaxis” and “inflammatory response” in
DPN pathogenesis.13 As these animals manifest with early DKD,14
FIGURE 2 Effects of MK-0812 on DPN and DKD. Neuropathy
phenotyping consisted of measuring latency of hindpaw withdrawal
from a thermal stimulus (A), quantification of intraepidermal nerve
fiber (IENF) density (B) and assessment of sural sensory (C) (SNCV)
and sciatic motor (D) (MNCV) nerve conduction velocity.
Nephropathy was assessed by urinary ACR (E), urine volume (F),
mesangial index, expressed as PAS-positive glomerular area divided
by total glomerular area (G) and total glomerular area (H). **P < .001;
***P < .0001 ob/ob mice vs ob/+ mice. δδP < .001 MK-0812-treated
ob/+ and ob/ob mice vs respective non-treated controls
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the current study sought to investigate whether targeting a common
inflammatory pathway would have restorative effects by attenuating
microvascular complications.
Contrary to our hypothesis, MK-0812 treatment evoked no
improvement in DKD or DPN in ob/ob mice and was also insufficient
in mitigating hyperglycaemia or hyperinsulinaemia. Despite the
absence of predicted effects, however, MK-0812 decreased adipose
inflammation in ob/ob mice by reducing concentrations of Cd68, F4/
80 and Tnfα.13 MK-0812-treated ob/ob mice also displayed a modest
decrease in %GHb relative to untreated controls that could be attrib-
uted to the decrease in adipose tissue inflammation, but the improve-
ment was insufficient to surmount the metabolic derangements
characteristic of T2D.10 These results conflict with independent stud-
ies in which CCR2 inhibition prevented DKD in mice10 and humans.11
Kang et al. observed improvements in renal function of C57BKS db/
db mice treated for 12 weeks with the CCR2 antagonist RS504393,10
while CCR2 inhibition reduced proteinuria in humans with T2D and
DKD.11
We anticipate that the primary reason MK-0812 had largely no
effect on metabolic parameters or diabetic complications is related to
features of the ob/ob mouse model itself. Previous studies demon-
strating a positive effect of CCR2 antagonists on DKD have almost
exclusively used db/db mice10 that do not develop the aggressive
hyperglycaemia or DKD phenotype seen in ob/ob mice.14 This sug-
gests that the likelihood of an intervention successfully attenuating
disease in db/db mice will be higher than that in a more aggressive
T2D model. In addition, although db/db mice lack the long isoforms
of hypothalamic leptin receptor, short leptin receptor isoforms are
expressed on the kidney and vasculature, and leptin-leptin receptor
binding may confer a slight protection against DKD development that
is absent in leptin-deficient ob/ob mice.15 Another caveat of this
model stems from the fact that we observed no difference in markers
of inflammation in plasma, kidney or nerve between control and ob/
ob mice. Inflammation is heavily implicated in DKD development in
mouse models of T2D that have functional leptin.3 As leptin has
numerous important immunomodulatory actions, a deficiency can
compromise normal immune homeostasis. Hence, the atypical inflam-
matory signaling present in ob/ob mice may not be suitable to explore
therapies targeting inflammation. Observations from this study fur-
ther suggest that DKD and DPN pathogenesis are independent of
increases in kidney or nerve pro-inflammatory mediators in this
model. Finally, we ensured that the lack of a positive effect on
DKD/DPN was not the result of an ineffective dose of MK-0812 by
looking directly at adipose tissue inflammation, a known driver of
metabolic dysfunction.1 Similar to Kang et al. who demonstrated that
CCR2 antagonism decreases adipose tissue inflammation in C57BKS
db/db mice,10 we observed a decrease in inflammatory markers fol-
lowing MK-0812 treatment in ob/ob mice, thus confirming that the
lack of MK-0812 therapeutic efficacy on microvascular complications
in ob/ob mice was not simply the result of inadequate drug activity.
In summary, MK-0812 had no effect on the metabolic para-
meters or the severity of DPN and DKD in ob/ob mice. These obser-
vations are unexpected, given previous independent reports of its
efficacy in improving both glycaemic control and DKD in db/db
mice.10 We speculate that MK-0812 treatment in alternate models,
such as db/db or diet-induced obese mice, should be pursued, based
on the existing literature supporting a role for inflammation in the
onset and development of microvascular complications in humans as
well as these other models.
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